Ekso Bionics will release Q1 2025 financial results on May 5, followed by a conference call at 1:30 p.m. PT.
Quiver AI Summary
Ekso Bionics Holdings, Inc., a leader in exoskeleton technology for medical and industrial applications, will announce its financial and business results for the first quarter of 2025 on May 5, 2025, after market close. The company's management will hold a conference call at 1:30 p.m. PT to discuss the results and recent developments, with participation details provided for both domestic and international callers. The call will also be available for live streaming and archival on the company's website. Ekso Bionics focuses on advanced robotics to enhance human mobility and capabilities, serving various needs from medical assistance to industrial use, and is headquartered in the San Francisco Bay Area, trading on the Nasdaq under the symbol "EKSO."
Potential Positives
- Ekso Bionics is set to release its financial and business results, indicating transparency and accountability to investors.
- The scheduled conference call presents an opportunity for stakeholders to engage directly with management and discuss recent developments.
- The announcement reinforces Ekso Bionics' position as a leader in exoskeleton technology, showcasing its commitment to improving health and quality of life.
Potential Negatives
- None
FAQ
When will Ekso Bionics release its Q1 2025 financial results?
Ekso Bionics will release its financial results on May 5, 2025, after market close.
How can I join the Ekso Bionics conference call?
To join the conference call, dial 877-407-6184 for domestic calls or 201-389-0877 for international calls.
What time is the conference call for Q1 2025 results?
The conference call will begin at 1:30 p.m. PT / 4:30 p.m. ET.
Where can I find the archived conference call?
The archived call will be available on the Ekso Bionics website under “Presentations & Events” in the Investors section.
What does Ekso Bionics specialize in?
Ekso Bionics specializes in developing exoskeleton technology to enhance human strength, endurance, and mobility for medical and industrial uses.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EKSO Hedge Fund Activity
We have seen 12 institutional investors add shares of $EKSO stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE PR LLC removed 669,700 shares (-40.1%) from their portfolio in Q4 2024, for an estimated $408,517
- ARMISTICE CAPITAL, LLC removed 441,351 shares (-20.4%) from their portfolio in Q4 2024, for an estimated $269,224
- CRESSET ASSET MANAGEMENT, LLC removed 215,615 shares (-41.8%) from their portfolio in Q4 2024, for an estimated $131,525
- FNY INVESTMENT ADVISERS, LLC added 52,500 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,157
- GOLDEN STATE WEALTH MANAGEMENT, LLC added 19,505 shares (+100.0%) to their portfolio in Q1 2025, for an estimated $7,860
- HRT FINANCIAL LP added 13,427 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,190
- ATRIA WEALTH SOLUTIONS, INC. removed 12,667 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $7,726
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company’s website at www.eksobionics.com under “Presentations & Events” in the Investors section.
About Ekso Bionics
®
Ekso Bionics
®
is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry-leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Ekso Bionics is the only known exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit:
www.eksobionics.com
.
Contact:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email:
[email protected]
